(3S)-3-amino-4-[(2S)-2,5-diaminopentanoyl]oxy-4-oxobutanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S)-3-amino-4-[(2S)-2,5-diaminopentanoyl]oxy-4-oxobutanoic acid
• 化学式: C₉H₁₇N₃O₅
• 分子量: 247.25
• InChiKey: VVCVWIOCXUDYFJ-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.9
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  159
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• COMPOSITION OF PROTECTORS OF ACUTE AND CHRONIC HEPATIC ENCEPHALOPATHY AND METHOD FOR TREATING ACUTE AND CHRONIC HEPATIC ENCEPHALOPATHY
  申请人：Obshchestvo S Ogranichennoj Otvetstvennostju «Biotekhnologii Pyshchino»

  公开号：EP2792354A2

  公开（公告）日：2014-10-22

  The invention relates to medicine and concerns pharmaceutical compositions (formulations) which can be made also, including in the form of dietary supplements, having the properties of protectors of hepatic encephalopathy and hepatoprotectors , including : - Acute (fulminant) hepatic encephalopathy caused by acute liver failure ; - Chronic hepatic encephalopathy, in which the underlying etiology - cirrhosis of the liver caused by alcoholic , non-alcoholic or viral hepatitis , etc. The invention consists in that: the treatment of acute and chronic hepatic encephalopathy include complex compositions, whose components have a synergistic effect on various metabolic and signaling systems , including the activation of: osmoprotectant and energetic systems; detoxification reactions of ammonium ion and other toxins ; antioxidant systems of brain and liver cells, and of other tissues and organs. Compositions for the treatment of acute hepatic encephalopathy contain as a base : L- carnitine , acetyl -L- carnitine and phosphocreatine , and may also contain : N- acetylcysteine and ethanol (1); succinate , L- glutamate , L- arginine, N- acetylcysteine and betaine (2); succinate , L- glutamate , L- arginine, and betaine (3); Compositions for the treatment of chronic hepatic encephalopathies, as bases comprise : L-carnitine , acetyl -L- carnitine , succinate , L- glutamate , L- arginine, betaine, and phosphocreatine , and may also contain : N- acetylcysteine, coenzyme Q10 and dihydroquercetin (4); S- adenosyl methionine , coenzyme Q10 and dihydroquercetin (5); S- adenosyl methionine , coenzyme Q10, dihydroquercetin and lipoamide (6). The invention provides the means (preparations) to expand the arsenal of the treatment of the treatment of acute and chronic hepatic encephalopathy,the means hindering the development of coma and death in acute hepatic encephalopathy and providing reverse development of behavioral, neurological and mental disorders in chronic encephalopathy.

  本发明与药物有关，涉及药物组合物（制剂），也可制成膳食补充剂等形式，具有肝性脑病保护剂和保肝剂的特性，包括......： - 由急性肝功能衰竭引起的急性（暴发性）肝性脑病； - 慢性肝性脑病，其基本病因是酒精性、非酒精性或病毒性肝炎等引起的肝硬化。 本发明包括：治疗急性和慢性肝性脑病的复方组合物，其成分对各种代谢和信号系统具有协同作用，包括激活：渗透保护剂和能量系统；铵离子和其他毒素的解毒反应；脑和肝细胞以及其他组织和器官的抗氧化系统。 治疗急性肝性脑病的复方制剂以 L-肉碱、乙酰-L-肉碱和磷酸肌酸为基础，还可能含有：N-乙酰半胱氨酸和乙醇 (1)；琥珀酸盐、L-谷氨酸、L-精氨酸、N-乙酰半胱氨酸和甜菜碱 (2)；琥珀酸盐、L-谷氨酸、L-精氨酸和甜菜碱 (3)； 用于治疗慢性肝性脑病的组合物，作为基质包括：L-肉碱、乙酰-L-肉碱、琥珀酸、L-谷氨酸、L-精氨酸、甜菜碱和磷酸肌酸，还可能含有：N-乙酰半胱氨酸、辅酶 Q10 和二氢槲皮素（4）；S-腺苷蛋氨酸、辅酶 Q10 和二氢槲皮素（5）；S-腺苷蛋氨酸、辅酶 Q10、二氢槲皮素和脂酰胺（6）。 本发明提供了扩大治疗急性和慢性肝性脑病的手段（制剂），阻碍急性肝性脑病患者昏迷和死亡的发展，并逆转慢性脑病患者行为、神经和精神障碍的发展。